Subcutaneously Administered Recombinant Human Interleukin-2 and Interferon Alfa-2a for Advanced Breast Cancer: A Phase II study of the Cancer and Leukemia Group B (CALGB 9041)

Author： Kimmick Gretchen   Ratain Mark J.   Berry Don   Woolf Susan   Norton Larry   Muss Hyman B.  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.22, Iss.1, 2004-01, pp. : 83-89

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: Results from Cancer and Leukemia Group B 19808

By Kolitz Jonathan E.   George Stephen L.   Benson Don M.   Maharry Kati   Marcucci Guido   Vij Ravi   Powell Bayard L.   Allen Steven L.   DeAngelo Daniel J.   Shea Thomas C.   Stock Wendy   Bakan Courtney E.   Hars Vera   Hoke Eva   Bloomfield Clara D.   Caligiuri Michael A.   Larson Richard A.    

Cancer, Vol. 120, Iss. 7, 2014-04 ,pp. : 1010-1017

Blackwell Publishing

Access to resources Recommend Favorite

Comparative Pharmacokinetics, Tissue Distribution, Excretion of Recombinant Liver-Targeting Interferon with IFN α2b Administered Intramuscular in Rats

By  

Current Pharmaceutical Biotechnology, Vol. 16, Iss. 10, 2015-01 ,pp. : 911-919

Bentham Science Publishers

Access to resources Recommend Favorite

Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study

By Boér Katalin  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 681-687

Springer Publishing Company

Access to resources Recommend Favorite

Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: A Southwest Oncology Group study

By Whitehead Robert   McCoy Sheryl   Macdonald John   Rivkin Saul   Neubauer Marcus   Dakhil Shaker   Lenz Heinz-Josef   Tanaka Michael   Abbruzzese James  

Investigational New Drugs, Vol. 24, Iss. 4, 2006-07 ,pp. : 335-341

Springer Publishing Company

Access to resources Recommend Favorite

Phase II trial of dolastatin-10 in patients with advanced breast cancer

By Perez Edith   Hillman David   Fishkin Paul   Krook James   Tan Winston   Kuriakose Phillip   Alberts Steven   Dakhil Shaker  

Investigational New Drugs, Vol. 23, Iss. 3, 2005-06 ,pp. : 257-261

Springer Publishing Company

Access to resources Recommend Favorite